Current scientific issues related to clinical radiation oncology

Radiation Research

Volumn 150, Issue 2, 1998, Pages 125-133

  Coleman, C Norman ^a   Harris, Jay R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CONFERENCE PAPER; CYTOPATHOGENIC EFFECT; HUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; TARGET CELL DESTRUCTION;

APOPTOSIS; CELL SURVIVAL; HUMANS; NEOPLASMS; PROGNOSIS;

EID: 0031854164     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.2307/3579848     Document Type: Conference Paper

References (52)

1. C. N. Coleman, T. W. Griffin, L. R. Prosnitz, R. T. Hoppe and J. S. Cooper, Training the radiation oncologist for the twenty-first century. Int. J. Radiat. Oncol. Biol. Phys. 35, 821-826 (1996).
2. C. N. Coleman, Clinical applications of molecular biology in radiation oncology. Semin. Radiat. Oncol. 6, 245-249 (1996).
3. A. G. Knudson, Hereditary cancer, oncogenes and antioncogenes. Cancer Res. 45, 1437-1443 (1985).
4. C. Eng, F. P. Li, D. H. Abramson, R. M. Ellsworth, F. L. Wang, M. B. Goldman, J. Seddon, N. Tarbell and J. D. Boice, Jr., Mortality from second tumors among long-term survivors of retinoblastoma. J. Natl. Cancer Inst. 85, 1121-1128 (1993).
5. J. D. Roarty, I. W. McLean and L. E. Zimmerman, Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 95, 1583-1587 (1988).
6. D. Malkin, F. P. Li, L. C. Strong, J. F. Fraumeni, Jr., C. E. Nelson, D. H. Kim, J. Kassel, M. A. Gryka, F. Z. Bischoff, M. A. Tainsky and S. H. Friend, Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238 (1990).
7. P. Kahn, Coming to grips with genes and risk. Science 274, 496-498 (1996). [News]
8. R. Nowak, Discovery of AT gene sparks biomedical research bonanza. Science 268, 1700-1702 (1995). [News]
9. A. R. Feinstein, D. M. Sosin and C. K. Wells, The Will Rogers Phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N. Engl. J. Med. 312, 1604-1608 (1985).
10. C. A. Quiet, D. J. Ferguson, R. R. Weichselbaum and S. Hellman, Natural history of node-positive breast cancer: The curability of small cancers with a limited number of positive nodes. J. Clin. Oncol. 14, 3105-3111 (1996).
11. A. J. Nixon, S. J. Schnitt, R. Gelman, I. Gage, B. Bornstein, S. Hetelekidis, A. Recht, B. Silver, J. R. Harris, and J. Connolly, JL. Relationship of tumor grade to other pathologic features and to treatment outcome of patients with early stage breast carcinoma treated with breast-conserving therapy. Cancer 78, 1426-1431 (1996).
12. R. Gelman, R. Gelber, I. C. Henderson, C. N. Coleman and J. R. Harris, Improved methodology for analyzing local and distant recurrence. J. Clin. Oncol. 8, 548-555 (1990).
13. I. Gage, A. Nixon, S. Schnitt, A. Recht, R. Gelman, B. Silver, J. Connolly and J. Harris, Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy. Int. J. Radiat. Oncol. Biol. Phys. 32 (Suppl. 1), 210 (1995). [Abstract]
14. J. A. Brennan, L. Mao, R. H. Huron, J. O. Boyle, Y. J. By, W. M. Koch, S. N. Goodman and D. Sidransky, Molecular assessment of histopathological staging in squamous cell carcinoma of the head and neck. N. Engl. J. Med. 332, 429-135 (1995).
15. L. M. Weiss, R. A. Warnke, J. Sklar and M. L. Cleary, Molecular analysis of the t(14:18) translocation in malignant lymphomas. N. Engl. J. Med. 317, 1185-1189 (1987).
16. C. A. Olsson, G. M. deVries, A. J. Raffo, M. C. Benson, K. O'Toole, Y. Cao, R. E. Buttyan and A. E. Katz, Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J. Urol. 155, 1557-1562 (1996).
17. E. J. Hall, Radiobiology for the Radiologist, 4th ed., pp. 29-45 and 245-246. J. B. Lippincott, Philadelphia, 1994.
18. B. Fertil and E. P. Malaise, Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: Analysis of 101 published survival curves. Int. J. Radiat. Oncol. Biol. Phys. 11, 1699-1707 (1985).
19. P. J. Deschavanne and B. Fertil, A review of human cell radiosensitivity in vitro. Int. J. Radiat. Oncol. Biol. Phys. 34, 251-266 (1996).
20. C. M. L. West, S. E. Davidson, P. A. Burt and R. D. Hunter, The intrinsic radiosensitivity of cervical carcinoma: Correlations with clinical data. Int. J. Radiat. Oncol. Biol. Phys. 31, 841-846 (1995).
21. J. C. Horiot, R. LeFur, T. N'Guyen, C. Chenal, S. Schraub, S. Alfonsi, G. Gardini, W. van den Bogaert, S. Danczak, M. Bolla, M. van Glabbeke and M. de Paw, Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother. Oncol. 25, 231-241 (1992).
22. K. K. Ang and L. J. Peters, Eds., Altered Fractionation in Radiation Oncology. Supplement to Cancer: Principles and Practice of Oncology (V. T. DeVita, Jr., S. Hellman and S. A. Rosenberg, Eds.), Vol. 8, no. 4. J. B. Lippincott, Philadelphia, 1994.
23. J. D. Cox, T. F. Pajak, V. A. Marcial, L. Coia, M. Mohiuddin, K. K. Fu, H. Selim, P. Rubin and H. Ortiz, Interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: Results from the RTOG protocol 8313. Int. J. Radiat. Oncol. Biol. Phys. 20, 1191-1195 (1991).
24. E. J. Hall, Radiobiology for the Radiologist. 4th ed., pp. 15-27. J. B. Lippincott, Philadelphia, 1994.
25. S. Powell and T. J. McMillan, DNA damage and repair following treatment with ionizing radiation. Radiother. Oncol. 19, 95-108 (1990).
26. R M. Sutherland, W. A. Ausserer, B. J. Murphy and K. R. Laderoute, Tumor hypoxia and heterogeneity: Challenges and opportunities for the future. Semin. Radiat. Oncol. 6, 59-70 (1996).
27. C. N. Coleman, Radiation and chemotherapy sensitizers and protectors. In Cancer Chemotherapy and Biotherapy (B. A. Chabner and D. L. Longo, Eds.), pp. 553-584. Lippincott-Raven, Philadelphia, 1996.
28. M. Nordsmark, M. Overgaard and J. Overgaard, Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41, 31-39 (1996).
29. J. A. Raleigh, M. W. Dewhirst and D. E. Thrall, Measuring tumor hypoxia. Semin. Radiat. Oncol. 6, 37-45 (1996).
30. M. Höckel, K. Schlenger, M. Mitze, U. Schaffer and P. Vaupel, Hypoxia and radiation response in human tumors. Semin. Radiat. J Oncol. 6, 3-9 (1996).
31. A. C. Begg, I. Hofland, L. Moonen, H. Bartelink, S. Schraub, P. Bontemps, R. LeFur, W. van den Bogaert, R. Caspers, M. van Glabbeke and J. C. Horiot, The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 19, 1559-1553 (1990).
32. R. Corvo, W. Giaretti, G. Sanguineti, E. Geido, R. Orecchia, M. Guenzi, G. Margarino, A. Bacigalupo, G. Garaventa, M. Barberi and V. Vitale, In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J. Clin. Oncol. 13, 1843-1850 (1995).
33. pot! J. Clin. Oncol. 32, 1539-1541 (1995).
34. H. Stellar, Mechanisms and genes of cellular suicide. Science 267, 1445-1449 (1995).
35. C. B. Thompson, Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456-1462 (1995).
36. T. G. Graeber, C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W. Lowe and A. J. Giaccia, Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91 (1996).
37. L. C. Stephens, N. R. Hunter, K. K. Ang, L. Milas and R. E. Meyn, Development of apoptosis in irradiated murine tumors as a function of time and dose. Radiat. Res. 135, 75-80 (1993).
38. I. F. Tannock, Treatment of cancer with radiation and drugs. J. Clin. Oncol. 14, 3156-3174 (1996).
39. G. G. Steel, The search for therapeutic gain in the combination of radiotherapy and chemotherapy. Radiother. Oncol. 11, 31-53 (1988).
40. Early Breast Cancer Trialists' Collaborative Group, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339, 1-15, 71-85 (1992).
41. M. V. Pilepich, R. Caplan, R. W. Byhardt, C. A. Lawton, M. J. Gallagher, J. B. Mesic, G. E. Hanks, C. T. Coughlin, A. Porter, W. U. Shipley and D. Grignon, Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of the Radiation Therapy Oncology Group Protocol 85-31. J. Clin. Oncol. 15, 1013-1021 (1997).
42. M. S. Anscher, T. Murase, D. M. Prescott, L. B. Marks, H. Reisenbichler, G. C. Bentel, D. Spenser, G. Sherhouse and R. L. Jirtle, Changes in plasma TGFβ levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int. J. Radial. Oncol. Biol. Phys. 30, 671-676 (1994).
43. P. Rubin, C. J. Johnston, J. P. Williams, S. McDonald and J. N. Finkelstein, A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int. J. Radiat. Oncol. Biol. Phys. 33, 99-109 (1995).
44. R. C. Miller, P. LaNansa and W. R. Hanson, Misoprostol-induced radioprotection of Syrian hamster embryo cells in utero from cell death and oncogenic transformation. Radiat. Res. 139, 109-114 (1994).
45. J. E. Moulder, B. L. Fish and E. P. Cohen, Treatment of nephropathy with ACE inhibitors. Int. J. Radiat. Oncol. Biol. Phys. 27, 93-99 (1993).
46. J-L. Lefaix, S. Delanian, J-J. Leplat, T. Trichaud, M. Martin, A. Nimrod, F. Baillet and F. Daburon, Successful treatment of radiation-induced fibrosis using Cu/Zn-SOD and Mn-SOD: An experimental study. Int. J. Radiat. Oncol. Biol. Phys. 35, 305-312 (1996).
47. R. K. Jain, Barriers to drug delivery in solid tumors. Sci. Am. 271, 58-65 (1994).
48. D. McCurdy, L. Q. Tai, S. Frias and Z. Wang, Delayed repair of DNA damage by ionizing radiation in cells from patients with juvenile systemic lupus erythematosis and rheumatoid arthritis. Radiat. Res. 147, 48-54 (1997).
49. A. P. Forrest, H. J. Stewart, D. Everington, R. J. Prescott, C. S. McArdle, A. N. Harnett, D. C. Smith and W. D. George, Randomized controlled trial of conservative therapy for breast cancer: 6-year analysis of the Scottish trial. Lancet 348, 708-713 (1996).
50. B. Fisher, J. Digraw, J. Bryant, A. DeCillis, D. L. Wickerham, N. Wolmark, J. Costantion, C. Redmond, E. R. Fisher, D. M. Bowman, L. Deschenes, N. V. Dimitrov, R. G. Margolese, A. Robidoux, H. Shibata, J. Terz, A. H. G. Paterson, M. I. Feldman, W. Farrar, J. Evans and H. L. Lickley, Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor positive tumors. J. Natl. Cancer Inst. 88, 1529-1542 (1996).
51. M. Overgaard, P. S. Hansen, J. Overgaard, C. Rose, M. Anderson, F. Bach, J. Kjaer, C. C. Gadeberg, H. T. Mouridsen, M. B. Jensen and K. Zedeler, Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N. Engl. J. Med. 337, 949-955 (1997).
52. J. Ragaz, S. M. Jackson, N. Le, I. H. Plenderleith, J. J. Spinelli, V. E. Basco, K. S. Wilson, M. A. Knowling, C. M. L. Coppin, M. Paradis, A. J. Coldman and I. A. Olivotto, Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 337, 956-962 (1996).